Lupin launches azilsartan medoxomil tablets in US after FDA approval
Business
Lupin just rolled out Azilsartan medoxomil tablets in the US after getting FDA approval.
This generic version of Edarbi helps lower blood pressure and comes in 40-mg and 80-mg doses.
Lupin wins 180 days US exclusivity
Lupin scored 180 days of exclusive rights as the first generic on the market, a smart move since Edarbi pulled in about $53.5 million in US sales during the 12 months ended April 2026.
With recent wins like its Sutab generic, Lupin expects its US revenue to top $1 billion by fiscal 2027.
CEO Vinita Gupta says biosimilars and specialty meds are key for growth, while Executive Director and Global CFO Ramesh Swaminathan is aiming for steady margins even with tough competition ahead.